Tags

Type your tag names separated by a space and hit enter

Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.
Am J Epidemiol 2011; 173(12):1419-28AJ

Abstract

This study examined the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer risk in 5,068 placebo-arm participants enrolled in the Prostate Cancer Prevention Trial (1993-2003). These data include 1,225 men whose cancer was detected during the 7-year trial--556 detected for cause (following abnormal prostate-specific antigen or digital rectal examination) and 669 detected not for cause (without indication), as well as 3,843 men who had biopsy-proven absence of prostate cancer at the trial end. Symptomatic BPH was assessed hierarchically as self-report of surgical or medical treatment, moderately severe symptoms (International Prostate Symptom Score >14), or physician diagnosis, and analyses were completed by BPH status at baseline (prevalent) or BPH prior to cancer diagnosis or study end (prevalent plus incident). Controlled for age, race, and body mass index, neither prevalent (risk ratio = 1.03, 95% confidence interval: 0.92, 1.14) nor prevalent plus incident (risk ratio = 0.96, 95% confidence interval: 0.87, 1.06) symptomatic BPH was associated with prostate cancer risk. This lack of association was consistent across subgroups defined by type of BPH-defining event (treatment, symptoms, or physician diagnosis), prompt for prostate cancer diagnosis, and prostate cancer grade. This study provides the strongest evidence to date that BPH does not increase the risk of prostate cancer.

Authors+Show Affiliations

Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. jschenk@fhcrc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

21540324

Citation

Schenk, Jeannette M., et al. "Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results From the Prostate Cancer Prevention Trial." American Journal of Epidemiology, vol. 173, no. 12, 2011, pp. 1419-28.
Schenk JM, Kristal AR, Arnold KB, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol. 2011;173(12):1419-28.
Schenk, J. M., Kristal, A. R., Arnold, K. B., Tangen, C. M., Neuhouser, M. L., Lin, D. W., ... Thompson, I. M. (2011). Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. American Journal of Epidemiology, 173(12), pp. 1419-28. doi:10.1093/aje/kwq493.
Schenk JM, et al. Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results From the Prostate Cancer Prevention Trial. Am J Epidemiol. 2011 Jun 15;173(12):1419-28. PubMed PMID: 21540324.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. AU - Schenk,Jeannette M, AU - Kristal,Alan R, AU - Arnold,Kathryn B, AU - Tangen,Catherine M, AU - Neuhouser,Marian L, AU - Lin,Daniel W, AU - White,Emily, AU - Thompson,Ian M, Y1 - 2011/05/03/ PY - 2011/5/5/entrez PY - 2011/5/5/pubmed PY - 2011/9/23/medline SP - 1419 EP - 28 JF - American journal of epidemiology JO - Am. J. Epidemiol. VL - 173 IS - 12 N2 - This study examined the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer risk in 5,068 placebo-arm participants enrolled in the Prostate Cancer Prevention Trial (1993-2003). These data include 1,225 men whose cancer was detected during the 7-year trial--556 detected for cause (following abnormal prostate-specific antigen or digital rectal examination) and 669 detected not for cause (without indication), as well as 3,843 men who had biopsy-proven absence of prostate cancer at the trial end. Symptomatic BPH was assessed hierarchically as self-report of surgical or medical treatment, moderately severe symptoms (International Prostate Symptom Score >14), or physician diagnosis, and analyses were completed by BPH status at baseline (prevalent) or BPH prior to cancer diagnosis or study end (prevalent plus incident). Controlled for age, race, and body mass index, neither prevalent (risk ratio = 1.03, 95% confidence interval: 0.92, 1.14) nor prevalent plus incident (risk ratio = 0.96, 95% confidence interval: 0.87, 1.06) symptomatic BPH was associated with prostate cancer risk. This lack of association was consistent across subgroups defined by type of BPH-defining event (treatment, symptoms, or physician diagnosis), prompt for prostate cancer diagnosis, and prostate cancer grade. This study provides the strongest evidence to date that BPH does not increase the risk of prostate cancer. SN - 1476-6256 UR - https://www.unboundmedicine.com/medline/citation/21540324/Association_of_symptomatic_benign_prostatic_hyperplasia_and_prostate_cancer:_results_from_the_prostate_cancer_prevention_trial_ L2 - https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwq493 DB - PRIME DP - Unbound Medicine ER -